Literature DB >> 12604352

PAX4 mutation (R121W) as a prodiabetic variant in Okinawans.

Yoshinori Shimajiri1, Michio Shimabukuro, Takeaki Tomoyose, Hiroyuki Yogi, Ichiro Komiya, Nobuyuki Takasu.   

Abstract

We previously reported that a missense mutation at codon 121 (CGG(Arg) to TGG(Trp), R121W) of PAX4 may be associated with the onset of type 2 diabetes in Japanese. In this study, we determined the frequency of the R121W mutation of PAX4 and characterized the prodiabetic phenotype in a population-based study. Healthy 372 residents participated in annual health check-ups in Nishihara (Okinawa, Japan) and unrelated 193 type 2 diabetic patients from the outpatient clinic of Ryukyu University Hospital were enrolled. Diagnosis of diabetes was based on the 1997 American Diabetes Association criteria. The R121W mutation in PAX4 was genotyped by PCR-RFLP analysis. In healthy residents, R121W mutation was detected in 12 of 372 residents (3.1%). The prevalence of newly diagnosed type 3 diabetes (25% vs. 5%, p=0.004) and HbA(1c) (5.6+/-1.9 vs. 5.1+/-0.7, p=0.026) was higher in the variants than in the wild-types. The odds ratio of diabetes in the R121W variants was 5.98 with 95% confidence interval from 1.50 to 23.9. The R121W mutation was observed in 12 of the 193 type 2 diabetic patients (6.2%). Onset-ages of diabetes were earlier (37+/-10 vs. 47+/-13 years, p=0.010) and the rate of insulin user was two times higher (83% vs. 41%, p=0.005) in the variants. The R121W mutation in PAX4 is a predisposing factor for the development of type 2 diabetes in Okinawans.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12604352     DOI: 10.1016/s0006-291x(03)00176-1

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  NeuroD1 A45T and PAX4 R121W polymorphisms are associated with plasma glucose level of repaglinide monotherapy in Chinese patients with type 2 diabetes.

Authors:  Zhi-Cheng Gong; Qiong Huang; Xing-Ping Dai; Guang-Hua Lei; Hong-Bin Lu; Ji-Ye Yin; Xiao-Jing Xu; Jian Qu; Qi Pei; Min Dong; Bo-Ting Zhou; Jie Shen; Gan Zhou; Hong-Hao Zhou; Zhao-Qian Liu
Journal:  Br J Clin Pharmacol       Date:  2012-09       Impact factor: 4.335

Review 2.  Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.

Authors:  Gaia Chiara Mannino; Giorgio Sesti
Journal:  Mol Diagn Ther       Date:  2012-10       Impact factor: 4.074

3.  No association of the IRS1 and PAX4 genes with type I diabetes.

Authors:  R Bergholdt; C Brorsson; B Boehm; G Morahan; F Pociot
Journal:  Genes Immun       Date:  2009-12       Impact factor: 2.676

4.  Wnt signaling in caudal dysgenesis and diabetic embryopathy.

Authors:  Gabriela Pavlinkova; J Michael Salbaum; Claudia Kappen
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2008-10

5.  In vivo conditional Pax4 overexpression in mature islet β-cells prevents stress-induced hyperglycemia in mice.

Authors:  Kai Hui Hu He; Petra I Lorenzo; Thierry Brun; Carmen M Jimenez Moreno; Deborah Aeberhard; Jorge Vallejo Ortega; Marion Cornu; Fabrizio Thorel; Asllan Gjinovci; Bernard Thorens; Pedro L Herrera; Paolo Meda; Claes B Wollheim; Benoit R Gauthier
Journal:  Diabetes       Date:  2011-04-26       Impact factor: 9.461

6.  The diabetes-linked transcription factor PAX4 promotes {beta}-cell proliferation and survival in rat and human islets.

Authors:  Thierry Brun; Isobel Franklin; Luc St-Onge; Anna Biason-Lauber; Eugene J Schoenle; Claes B Wollheim; Benoit R Gauthier
Journal:  J Cell Biol       Date:  2004-12-13       Impact factor: 10.539

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.